Loading…

Loading grant details…

Completed H2020 European Commission

MITHAML – Exploring the role of Metabolic IntraTumoral Heterogeneity in drug resistance of Acute Myeloid Leukemia in vivo

€257.6K EUR

Funder European Commission
Recipient Organization Institut National de la Sante Et de la Recherche Medicale
Country France
Start Date Feb 01, 2021
End Date Jan 31, 2024
Duration 1,094 days
Number of Grantees 2
Roles Coordinator; Partner
Data Source European Commission
Grant ID 897140
Grant Description

Drug resistance is a major barrier in acute myeloid leukemia (AML) for which prognosis remains unfavorable.

We and others have shown the importance of metabolism in the response to therapies in AML, leading to the development of several drugs targeting mitochondrial functions such as BCL2 inhibitor Venetoclax or Electron Transfer Chain Complex I inhibitor IACS-010759.

Tumors are composed of genetically and phenotypically heterogeneous cell populations, not all cells being equal in their ability to respond to treatment.

Tremendous advances in single-cell technologies like mass cytometry (CyTOF) have demonstrated a fantastic potential to decipher this phenotypic and signaling heterogeneity.

However, metabolic features are mostly measured in bulk, impeding the assessment of the metabolic cellular heterogeneity.

We propose to investigate the role of metabolic intratumoral heterogeneity in AML at diagnosis and after new drugs in vivo through 2 aims.

First we will determine the relationship between metabolic, signaling and developmental states in healthy and leukemic myeloid bone marrow cells and its link with chemoresistance (Aim 1).

Then we will focus on the impact of Venetoclax and IACS on MITH in vivo using patient-derived xenograft mice models to identify specific features related to resistance to these drugs that we will finally therapeutically target with new combinations in vivo (Aim 2).

The skills of the experienced researcher (ER) on metabolism and omic technologies and the complementary expertise of the 2 laboratories are key for the success of MITHAML.

Indeed, the ER will be trained for 2-years in Dr Davis’s lab (Stanford University, USA), highly recognized in the study of intratumoral heterogeneity especially with CyTOF. She will then bring back these skills in Dr Sarry’s lab (Inserm, France), expert in in vivo AML resistance.

This fellowship will be key to help the ER develop the scientific, technological and management skills required for her independence.

All Grantees

Institut National de la Sante Et de la Recherche Medicale; Board of Trustees of the Leland Stanford Junior University

Advertisement
Discover thousands of grant opportunities
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant